Introduction

Current and future investments in proven HIV interventions will help address global health goals
Although having tapered, globally, the HIV epidemic has been the fastest growing cause of disease burden of the past 20 years and is second only to malaria in its amount of disease burden in sub-Saharan Africa (Institute for Health Metrics and Evaluation, 2013) . In the last decade, evidence has emerged of interventions that reduces HIV disease burden: HIV treatment (through antiretroviral therapy) once a person living with HIV (PLHIV) reaches a threshold CD4 count, male circumcision, comprehensive prevention programmes for key populations and condom promotion during casual sex. Of these, HIV treatment has received the most funding: in 2012, over half (55%) of the global total of USD 18.9 billion went towards AIDS financing in low and middle income countries (LMIC), was spent on HIV treatment (UNAIDS 2013). In both generalized and concentrated HIV epidemics, HIV treatment dominates budgets for HIV programs and services (Amico, Gobet, Avila-Figueroa, Aran & De Lay, 2012) . Although some care needs to be exerted in terms of assuming an impact in all populations, these current investments in proven HIV interventions, and future ones, can help to address global health goals, including those from the recent Lancet Commission report (Global Health 2035) to reduce deaths due to HIV/AIDS to 8 per 100 000 population (Jamison et al., 2013) .
The concept of expanding antiretroviral therapy (ART) coverage and access as a preventative HIV intervention at the population has gained much support within the global community. Here, we will discuss important aspects of HIV Treatment as Prevention (TasP), including its potential effectiveness, financing and implementation. Specifically, we will address the varying evidence of TasP effectiveness across different settings, with regard to its population-level impact on the HIV epidemic and more largely on health and social welfare. We will also discuss its cost-effectiveness and required financing for its implementation.
Finally, the many challenges associated with TasP implementation will be highlighted, along with strategies to address them. We maintain that TasP could be a great tool in our strategy to combat global HIV/AIDS, provided that careful consideration is given to how this intervention is implemented.
Earlier initiation of PLHIV on ARVs has the potential to amplify the contribution of HIV treatment on reducing HIV disease burden to less than 8 per 100 000 population
While the purpose of HIV treatment has been to reduce HIV-related morbidity and mortality, recent evidence has shown that ART can also have an effect on reducing new HIV infections. The landmark HIV Prevention Trials Network (HPTN) 052 study demonstrated the ability of ART (initiated at CD4 counts of less than 550 copies/ml) to reduce by 96%, through viral suppression, the risk of HIV transmission from an HIV positive person to his/her sexual partner (Cohen, Chen, McCauley, Gamble, Hosseinipour, Kumarasamy et al., 2011) .
Simultaneously, the study also showed that clinical outcomes (HIV-related morbidity and mortality) decreased with earlier ART initiation (Grinsztejn et al, 2014) . This study therefore proved definitely that ART not only reduced morbidity and mortality, but also new HIV infections: thus proving itself as essential in achieving the global health goal of reducing AIDS deaths to fewer than 8 per 100 000 population by 2035.
The results of this study gave rise to the concept of HIV Treatment as Prevention (TasP) -this refers to the notion of initiating people living with HIV (PLHIV) earlier on ART (either at CD4 count of 500, or even initiating them on HIV treatment at the point of HIV diagnosis) with the intention of reducing the risk of HIV transmission to their sexual partners and with anticipated wider effects of reducing HIV incidence in the population. There is evidence that ART use can reduce HIV risk within a population (Tanser, Barnighausen, Grapsa, Zaidi & Newell, 2013) ; as such, earlier ART initiation shows promise as an effective HIV prevention tool at population level. It is therefore important to examine the economics, logistics and feasibility of implementing TasP.
The effectiveness of TasP at the population level varies in different regions and populations
One important consideration with regard to the effect of TasP, is the contrast between efficacy of ARVs on preventing onward transmission at the individual level (96%, as per (Cohen et al., 2011) and the effectiveness of TasP (implemented in real life settings instead of in a clinical trial) at the population level. In real life implementation situations, where HIV diagnosis is harder, ART coverage is likely to be less than ideal, ART adherence and retention is likely to be lower, fewer persons are likely to be virally suppressed, resulting in lower population-level impact than individual-level efficacy of ART.
So far, data from real life implementation has shown that the contrast between individual level efficacy and population-level effectiveness can be quite dramatic:
In KwaZulu Natal, there was only a 34% reduction in HIV incidence rates between areas which recently reached 30-40% ART coverage versus areas with below 10% ART coverage (CD4 count <350) (Tanser et al., 2013) . Data from Swaziland suggest that high HIV incidence can be maintained even under high population-level ART coverage. An estimated 74% of adults (persons older than 15) needing ART (CD4 count <350) were enrolled in ART in 2011 in Swaziland (WHO, UNICEF & UNAIDS, 2013) . In the same year, the Swaziland HIV Incidence Measurement Survey (SHIMS) found that among those on ARVs, 85% had viral loads under 1 000 copies/milliliter (Justman, Ellman, Donnell, Duong, Reed, Bicego et al., 2013 ) and yet, that measured HIV incidence was 2.4% Other studies confirm that the population-level impact of ART on averting new infections may be much lower in real life. An observation study in discordant couples in China showed only 26% lower HIV incidence, and this protection was only maintained in transfusion or sexually infected groups, not those acquiring HIV through injecting drug use (Jia, Mao, Zhang, Ruan, Ma, Li et al., 2013) . A cohort study in Uganda did not show any differences in HIV incidence in discordant couples in a rural ART program (Birungi, Wang, Ngolobe, Muldoon, Khanakwa, King et al., 2013) . A key difference that may explain the discrepancy of results between these more recent studies and HPTN052 is CD4 count; CD4 count at initiation was at or below 250 in the Jia et al and Birungi et al studies, ART Coverage (%) HIV incidence (%) ART coverage (2006 for CD4 200, 2009 (Wilson, 2012) . In a large MSM study in England and Wales over a decade, the proportion of HIV-positive men with CD4 counts <350 taking ART rose from 69% to 80% and rates of HIV testing increased by 3.7 times. However, despite these improvements, the population-level incidence of HIV infection did not decrease in MSM (Birrell, Gill, Delpech, Brown, Desai, Chadborn et al., 2013) .
Clearly, the available data on TasP effectiveness at the population level are inconclusive, and a better understanding of the levels of ART coverage required to significantly impact an HIV epidemic is imperative for HIV programmatic efforts, especially as one considers the financial investment to implement TasP Successfully and effectively implementing TasP will be no menial feat, but doing so could have tremendous positive effects on the health, economies, and social welfare of countries. In South Africa, ART program rollout was associated with both a reduction by 20% in all adult mortality and an 11-year increase in life expectancy (Bor, Herbst, Newell & Barnighausen, 2013; Herbst, Cooke, Barnighausen, KanyKany, Tanser & Newell, 2009) (Martin, Devine, Eaton, Miners, Hallett, Foster et al., 2014) . The TB epidemic could similarly benefit from expanding ART eligibility and coverage.
Mathematical models predict a 6-30% decline in cumulative TB incidence over the period 2014 -2033 if ART eligibility was expanded to all HIV-positive individuals, and 28 -37% if expanded eligibility was combined with 80% ART coverage. Universal eligibility combined with 80% coverage could also reduce cumulative TB mortality by 13 -35% for that same period . This is an excellent example of how focusing on HIV treatment and prevention beneficially spills over into helping achieve other Global Health 2035 targets (reducing TB deaths).
TasP potential goes beyond its impact on health. Labor and education benefited from HIV treatment programs in both Botswana and Kenya. Absenteeism from work returned to pre-infection levels in Botswana (Habyarimana, Mbakile & PopEleches, 2010) , and Kenya experienced an increase in adult working hours and reductions in child labor, with higher attendance at school and better nutrition (Thirumurthy & Zivin, 2012) ).
TasP as a cost-effective HIV prevention tool in different settings
Aside from its social benefits, TasP implementation could be cost-effective and The suggested global health goals 2035 place a great focus on the convergence of health in LMIC closer to standards enjoyed in upper-middle income countries (UMIC). The report shows that the burden of global child mortality, AIDS and TB deaths rests overwhelmingly within LMICs including having the majority of prevalent and incident HIV cases (Jamison et al., 2013) .
At present, 43 LMICs finance over 75% of HIV treatment costs from international sources. In Malawi, HIV treatment is almost completely financed from external sources, and its costs are nearly equal to the country's total health budget.
However, the rapidly growing economies of the BRICS (Brazil, Russia, India, China, and South Africa) countries have enabled these countries to increase their own investment in HIV financing. South Africa currently has the second largest HIV budget globally (USD 1.9 billion) which grew by 500% in a decade v . Brazil
and Russia now fund almost all of their HIV programs, and China will completely do so after Global Fund resources end. India funds 93% of its HIV programs
The concept of a grand convergence will require that LMICs converge towards UMIC health standards, and it will also require that they close the current gap in external versus domestic funding for HIV programs in these countries. This is especially important as overall development assistance funding saw a 2 and 4% Commission's report does prioritize HIV prevention and early treatment, as this approach will work synergistically to reduce child mortality and deaths from TB (Jamison et al., 2013) .
All about implementation: need to get it right
Modelling suggests that earlier ART initiation is cost effective, and the potential of Identifying and enrolling this latter group, PLHIV who do not know their HIVpositive status due to being otherwise healthy (individuals with higher CD4 counts and at earlier stages of the disease), to ART will be a significant challenge to TasP. New effective targeted strategies for populations in geographic areas with the highest HIV prevalence, so as to increase the percentage of PLHIV that know their HIV status, are key to addressing this challenge. Equally, the challenges associated with reaching the stigmatized or marginalized populations should not be overlooked either; in concentrated HIV epidemics, these groups are responsible for driving transmission, yet, appropriately addressing the epidemic within these populations is complicated by lack of evidence on TasP effectiveness in them and highly politicized issues surrounding them (legality of homosexuality and prostitution in many countries and severity of punishment for drug users). Extending treatment -and indeed providing equitable access to health services -to these populations has not yet reached acceptable levels.
2) Challenges with ART initiation
Once a person is diagnosed with HIV, he/she is not immediately enrolled into ART or into a 'pre-ART' care program, and often he/she presents late for AIDS care at health facilities, even after an earlier HIV diagnosis. In Zambia, 43% of pre-ART patients were loss to follow up (LTFU), compared to 7% of patients 
3) Challenges with ART adherence and retention in care
Key challenges in long-term TasP Data on retention on ART over time suggest that losses can be very significant.
UNAIDS reports indicate that fewer than 60% of Malawians and less than 50% of Indonesians are retained on treatment after 5 years. Young adults (15 -24) living with HIV are also at greater risk for attrition after ART initiation than younger adolescents and older adults, but this risk can be reduced if adolescent support groups and sexual and reproductive health services are offered at the clinics they attend (Lamb, Fayorsey, Nuwagaba-Biribonwoha, Viola, Mutabazi, Alwar et al., 2014) . Even before ART initiation, it will be equally important to retain HIV-positive individuals within a system of monitoring and care, so that they may be enrolled in the treatment cohort at the appropriate time. Therefore, significant logistical and programmatic efforts will need to be made towards linking diagnosed HIV cases to ongoing medical provision and strengthening the retention of these individuals in a pre-treatment cohort to improve morbidity and mortality. One approach could be to use home-based care, including adherence support. A cluster-randomized trial in Uganda found that patients initiating ART and receiving home-based care had similar survival rates as those that received clinic-based care, even among those with very low CD4 counts (Woodd, Grosskurth, Levin, Amuron, Namara, Birunghi et al., 2014) .
4) Challenges with ART-related drug resistance if enrolled for long periods of time
Drug resistance to ARVs is another potential problem associated with implementation of TasP. Resistance to ARVs may occur due to poor adherence to ART or use of ARV regimens more susceptible to drug resistance. Expanding ART coverage to HIV-positive individuals with higher CD4 counts and otherwise feeling healthy may be associated with poor adherence in this population. This could be averted if first-line, once-daily ARVs with minimal side effects and less susceptibility to drug resistance are used. Additionally, if access to and availability of ARVs continues to be a problem during, or is the result of, ART scale-up, there is a greater risk for drug resistance to occur. One study suggests that acquired HIV drug resistance in low resource settings rises from over 5% in patients on less than one year of treatment to greater than 20% after 3 years (Stadeli & Richman, 2013) . Moreover, patients from countries with older ART programs (>5 years) were more likely to have transmitted drug resistance than those from younger programs (<5 years) (Stadeli & Richman, 2013) . The development of drug resistance in patients over their treatment duration has also been described in high-income countries (Phillips, Dunn, Sabin, Pozniak, Matthias, Geretti et al., 2005) . Furthermore, mathematical models expect transmitted drug resistance to increase throughout the course of an HIV epidemic, with respect to the baseline prevalence of drug resistance, and significantly impact mortality at the population level (Cambiano, Bertagnolio, Jordan, Lundgren & Phillips, 2013) . Thus, increasing drug resistance as treatment is scaled-up and as ART programs and HIV epidemics mature seems likely. To minimize this, significant financial, technical, and logistical resources will need to be put into ensuring access and adherence to first-line ARVs and careful monitoring of patients to detect and address ART failure as soon as it occurs.
Addressing implementation challenges and facilitating TasP
TasP can be facilitated through a variety of mechanisms in order to maximize cost-effectiveness and address its implementation challenges:
1) Prioritized ART access and scale-up can contribute to the economic feasibility of TasP and its cost-effectiveness.
Achieving high ART coverage under previous guidelines in some settings is a challenge associated with TasP One approach to this is focusing first on increasing access (HIV testing and linkage to care) to those most in need (CD4 counts <350) before extending ART eligibility to higher CD4 counts. In some settings, increasing access among HIV-positive adults with CD4 counts <350 may result in greater HIV incidence reductions over 20 years than expanding ART eligibility to higher CD4 counts. However, the latter may cost less per DALY averted (Eaton, Johnson, Salomon, Barnighausen, Bendavid, Bershteyn et al., 2012; Eaton et al., 2014) . Of note, these modeled analyses were carried out in countries with moderate to high ART coverage (South Africa and Zambia), and in settings with low coverage, expanding access within lower CD4 count groups may be more cost-effective. For concentrated epidemics such as in Vietnam and India, expanding ART eligibility within the general population is cost-effective, but increasing HIV testing and linkage to care should be focused on specific populations driving the epidemic .
2) Combining TasP with other high impact interventions
In a cost-effectiveness model of HIV prevention tools, it was found that high male circumcision and ART coverage (among HIV-positive individuals with CD4 counts <350) implemented together could reduce HIV incidence in South Africa to a similar degree as TasP, and this approach was estimated to be USD 5 billion less expensive than TasP implementation from 2009 to 2020 . The most cost-effective intervention, however, was increased male circumcision, costing USD 1 100 per infection averted, followed by high ART coverage (USD 6 800) and TasP (USD 8 400). As such, while TasP is costeffective, as per WHO guidelines, the authors here suggest that increased male circumcision and ART coverage is more so, and should be rolled out first.
3) Prioritized TasP scale-up in key populations at high risk of transmitting HIV
The best implementation strategies for specialized HIV-positive communities and their larger population in which they reside should also be investigated and employed to ensure the success of TasP. For instance, it was found that prioritizing access to care to female sex workers and their clients was the most efficient way to expand ART and avert remaining HIV infections within the general population in a ten year period in South India, rather than expanding ART eligibility (Mishra, Mountain, Pickles, Vickerman, Shastri, Gilks et al., 2014) .
4) Integrating HIV and health services
A strong focus on the strengthening and integration of health systems and interventions delivered across key delivery platforms, including community outreach, clinics, and hospitals will be needed. This is particularly important for LMICs, as they have limited resources (logistical, financial, and human) to expand health services, and many HIV-positive patients from LMICs are unable to access or remain in care, due to time and cost required to travel to health facilities. One way to address this for TasP is to "decentralize" HIV treatment from hospitals to health facilities or communities to facilitate patients' access to care and treatment. A review of studies in which patients were initiated or maintained on ART in a decentralized setting in LMICs found that ART initiated in a hospital and maintained in a health center appeared to have less attrition and loss to care than hospital alone (Kredo, Ford, Adeniyi & Garner, 2013) .
Moreover, decentralization did not result in worse health outcomes (Kredo et al., 2013) . Indeed, the Lancet Commission's report supports decentralization, as it maintains that clinics play an important role in healthcare service delivery and that many diseases can be treated at a primary care level, including HIV (Jamison et al., 2013) .
5) Task shifting
Task shifting of healthcare services is another way in which use of limited (human) resources can be maximized in biomedical HIV interventions, including
TasP. In Uganda, personnel costs were reduced by moving from a physicianintensive model for ART services to models that relied more heavily on nurses or pharmacy workers. In the latter scenario, costs were reduced by two-thirds (Babigumira, Sethi, Smyth & Singer, 2009) . Additionally, the best use of available resources should be considered. For instance, expanding ART eligibility will require more clinical monitoring of patients, including routine viral load testing, which might impair the process of expanding ART coverage and eligibility in limited resource settings. In these cases, it may be preferable to use resources towards earlier ART initiation rather than routine virological testing, as a modeling study using HIV data from East African countries showed the former to be a more cost-effective mechanism (Scott Braithwaite, Nucifora, Toohey, Kessler, Uhler, Mentor et al., 2014) . programs sites, decreasing as sites mature and acquire more patients (Menzies, Berruti & Blandford, 2012) . Along the same lines, treatment costs across national facilities can vary, and driving costs from less efficient, higher cost facilities to those more efficient, with lower costs is a strategy to increased overall HIV program efficiency in Kenya viii .
6)
7) Integration into UHC schemes
There is a global acknowledgement of the importance of include Universal Health Coverage (UHC), under which, by definition, essential health services must be available to all, free of financial hardship required to pay for them. UHC can support TasP scale-up where HIV testing, treatment and care are part of the essential package. Also, UHC calls for strong, efficient health systems to be in place, well-run by a cadre of skilled health workers, all required for TasP implementation and meeting Global Health 2035 goals. But, most importantly, UHC mandates access to affordable health services. Not only will this promote increased ART coverage, as more people are able to access it, but it will also support the cost-effectiveness of TasP. If TasP is to be included within the UHC framework, it will be required to remain financially feasible within national health budgets. To do so, additional financial allocation will need to be made to ARVbased interventions, which are, however, expected to be cost-saving in the long run (decreased HIV incidence, lower morbidity and mortality).
8) The use of incentives to improve HIV treatment outcomes and reduce unit costs
In regard to external funding of HIV/AIDS programs, a Results-Based Financing Financing and Coordination (Rottingen & Chamas, 2012) .
HIV R&D investment will also be important to logistically and financially facilitate licensing agreements with these companies (Waning, Diedrichsen & Moon, 2010) . The more LMIC manufacturers that are able to produce generic ARVs, the more competitive the market will become, driving costs down. This is especially needed for the more expensive first-line ART regimens.
It is equally important to continue socio-behavioral and operational research to evaluate HIV programs and determine which strategies work best. With regard to TasP, better ART adherence and retention strategies (based on evidence of what works) will be essential to securing long-term economic, health and social benefits of TasP.
10) Technological innovations
Technological innovation can lead to improved ART service delivery, better patient satisfaction, and better adherence and retention. A good example of this is how the Themba Lethu Clinic in South Africa, the world's largest ART center with 30,000 patients enrolled and 1,000 seen daily, cut back individual patient waiting time for ARV dispensing from upwards of 4.5 hours to 30 min with the use of an automated pharmacy robot. The robot connects to an integrated information and communications technology (ICT) system that is able to verify and validate a patient's electronic prescription, and within minutes, dispense the appropriate medication. Not only has this technology cut back patient waiting time, but it has also reduced the number of pharmacists needed, freeing them to attend patients in the wards (Mkize, 2013) . This successful integrated automated pharmacy machine and ICT system will be rolled out to three pilot sites in
Tshwane and it will be first trialed for HIV drug dispensing. Additionally, the use of mHealth and eHealth approaches, such as those used for patient tracking or to remind patients to take medication, to improve ART adherence and retention, and decrease loss to follow up rates, have been tried and works, but has not yet been rolled out at a national level in all ART programmes.
Conclusion
TasP implementation will require significant financial investment and massive, painstaking implementation efforts at local, national and global levels. In its early stages, there will be many challenges to address, with regard to ART scale-up and coverage levels required for TasP effectiveness in various populations and demographics. However, the positive externalities of ART go beyond the individual; the public health, economies, and society of the communities and states can also benefit from increased ART coverage. Moreover, while costly, analyses suggest that TasP is cost-effective in both generalized and concentrated HIV epidemics. As such, it can be considered a good health investment and fits well within Global Health 2035 goals.
Given cost and implementation challenges, implementing TasP effectively will require meticulous, incremental, patient-by-patient planning and action, while also upholding quality and expanding access through unremitting daily exertion and care. This is especially true for low-income countries with large epidemics, for which it must be emphasized that TasP is no magic short-cut. In these cases, TasP TasP as part of a high-impact HIV strategy will be a major undertaking. It challenges the global health and development community to excel in strategic planning, supply chain logistics and local program implementation, as well as devising sustainable financing mechanisms. TasP holds promise in driving the epidemic trajectory downwards while saving lives. And by making HIV-infected people live longer, more productive lives, we can hope to see invaluable socioeconomic gains.
